Compare BWA & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWA | QGEN |
|---|---|---|
| Founded | 1987 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 10.2B |
| IPO Year | 1993 | 1996 |
| Metric | BWA | QGEN |
|---|---|---|
| Price | $44.99 | $45.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 7 |
| Target Price | $46.93 | ★ $49.74 |
| AVG Volume (30 Days) | ★ 2.8M | 1.2M |
| Earning Date | 10-30-2025 | 02-04-2026 |
| Dividend Yield | 1.53% | ★ 3.34% |
| EPS Growth | N/A | ★ 331.20 |
| EPS | 0.61 | ★ 1.84 |
| Revenue | ★ $14,183,000,000.00 | $2,070,781,000.00 |
| Revenue This Year | $2.00 | $7.12 |
| Revenue Next Year | $2.43 | $6.13 |
| P/E Ratio | $72.92 | ★ $24.59 |
| Revenue Growth | 0.10 | ★ 5.32 |
| 52 Week Low | $24.40 | $37.63 |
| 52 Week High | $46.39 | $51.88 |
| Indicator | BWA | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 58.04 | 42.07 |
| Support Level | $41.63 | $44.82 |
| Resistance Level | $45.51 | $47.48 |
| Average True Range (ATR) | 0.81 | 0.60 |
| MACD | 0.22 | -0.18 |
| Stochastic Oscillator | 85.29 | 11.11 |
BorgWarner is a tier one supplier of turbo and thermal management technologies, drivetrain systems, powerdrive systems, and battery and charging systems mostly to automotive original equipment manufacturers. Its products aim to move a vehicle with as few electrons as possible, resulting in cleaner, cost-optimized, and more-efficient vehicles. Foundational products, the combustion vehicle business, contributes more than 80% to group revenue while BorgWarner transitions to becoming an electric vehicle-centric parts supplier (e-business). In 2024, 23% of the company's revenue was sourced from Volkswagen and Ford. Revenue is well diversified geographically, with approximately a third each generated in North America, Europe, and Asia.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).